Next Article in Journal
Special Issue: Candida and Candidiasis
Next Article in Special Issue
Present and Future Therapy of Cryptococcus Infections
Previous Article in Journal
Vitamin Biosynthesis as an Antifungal Target
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
J. Fungi 2018, 4(2), 73; https://doi.org/10.3390/jof4020073

Recent Advances in the Treatment of Scedosporiosis and Fusariosis

1
Division of General Internal Medicine, Weill Cornell Medicine of Cornell University, New York, NY 10065, USA
2
Department of Pediatrics, Division of Pediatric Infectious Diseases, Nationwide Children’s Hospital and The Ohio State University, Columbus, OH 43205, USA
3
Infectious Diseases Section, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, 54642 Thessaloniki, Greece
4
Transplantation-Oncology Infectious Diseases Program, Departments of Pediatrics, and Microbiology & Immunology, Weill Cornell Medicine, New York, NY 10065, USA
These authors contributed equally to this manuscript.
*
Author to whom correspondence should be addressed.
Received: 26 April 2018 / Revised: 13 June 2018 / Accepted: 16 June 2018 / Published: 18 June 2018
(This article belongs to the Special Issue Treatments for Fungal Infections)
Full-Text   |   PDF [289 KB, uploaded 18 June 2018]

Abstract

Species of Scedosporium and Fusarium are considered emerging opportunistic pathogens, causing invasive fungal diseases in humans that are known as scedosporiosis and fusariosis, respectively. These mold infections typically affect patients with immune impairment; however, cases have been reported in otherwise healthy individuals. Clinical manifestations vary considerably, ranging from isolated superficial infection to deep-seated invasive infection—affecting multiple organs—which is often lethal. While there have been a number of advances in the detection of these infections, including the use of polymerase chain reaction (PCR) and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF MS), diagnosis is often delayed, leading to substantial morbidity and mortality. Although the optimal therapy is controversial, there have also been notable advances in the treatment of these diseases, which often depend on a combination of antifungal therapy, reversal of immunosuppression, and in some cases, surgical resection. In this paper, we review these advances and examine how the management of scedosporiosis and fusariosis may change in the near future. View Full-Text
Keywords: fusariosis; scedosporiosis; isavuconazole; voriconazole; MALDI-TOF fusariosis; scedosporiosis; isavuconazole; voriconazole; MALDI-TOF
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

McCarthy, M.W.; Katragkou, A.; Iosifidis, E.; Roilides, E.; Walsh, T.J. Recent Advances in the Treatment of Scedosporiosis and Fusariosis. J. Fungi 2018, 4, 73.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Fungi EISSN 2309-608X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top